Sobrevida de pacientes con diagnóstico de linfoma tipo Burkitt en portadores del virus de inmunodeficiencia humana

Abstract

Introduction: Burkitt’s lymphoma (BL) is one of the most common neoplasms in patients with human immunodeficiency virus (HIV), due to the immune compromise they present. Patients with BZL who are HIV carriers have a survival rate of approximately 69 % two years after diagnosis. Aim: to describe the survival of patients diagnosed with Burkitt’s lymphoma in carriers of the Human Immunodeficiency Virus. Methodology: a narrative bibliographic review was carried out; for the bibliographic search information collected from the Pubmed database was used. Results: patients with HIV have a higher incidence of Burkitt type lymphoma due to their immunosuppression, so it is important that they adhere correctly to antiretroviral treatment and chemotherapy, since the survival of the mimics is between 45 % and 50 % 2 years after diagnosis. Conclusions: HIV carrier patients are approximately 100 times more likely to develop Burkitt’s lymphoma due to their deficient immune system. Currently, antiretroviral treatment has played a very important role in giving HIV carriers a fairly good quality of life.